DK0874621T3 - Lægemiddelemulsion indeholdende [3'-desoxy-3-oxy-MeBmt]1-[Val]2-ciclosporin - Google Patents

Lægemiddelemulsion indeholdende [3'-desoxy-3-oxy-MeBmt]1-[Val]2-ciclosporin

Info

Publication number: DK0874621T3
Authority: DK; Denmark
Prior art keywords: mebmt; cyclosporine; deoxy; val; oxy
Prior art date: 1996-01-19

Application number

DK97901563T

Other languages

English (en)

Inventor

Harry Tiemessen

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-01-19

Filing date

1997-01-20

Publication date

2003-09-01

1997-01-20 Application filed by Novartis Ag filed Critical Novartis Ag

2003-09-01 Application granted granted Critical

2003-09-01 Publication of DK0874621T3 publication Critical patent/DK0874621T3/da

Links

239000000839 emulsion Substances 0.000 title abstract 3
229960001265 ciclosporin Drugs 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
239000013543 active substance Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000003381 stabilizer Substances 0.000 abstract 2
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract 1
229930186217 Glycolipid Natural products 0.000 abstract 1
ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 abstract 1
ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000012141 concentrate Substances 0.000 abstract 1
235000014113 dietary fatty acids Nutrition 0.000 abstract 1
229930195729 fatty acid Natural products 0.000 abstract 1
239000000194 fatty acid Substances 0.000 abstract 1
150000004665 fatty acids Chemical class 0.000 abstract 1
238000001990 intravenous administration Methods 0.000 abstract 1
239000002960 lipid emulsion Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000003960 organic solvent Substances 0.000 abstract 1
150000003904 phospholipids Chemical class 0.000 abstract 1
229940068196 placebo Drugs 0.000 abstract 1
239000000902 placebo Substances 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1
150000003408 sphingolipids Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Immunology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Physical Education & Sports Medicine (AREA)
Dispersion Chemistry (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)

DK97901563T 1996-01-19 1997-01-20 Lægemiddelemulsion indeholdende [3'-desoxy-3-oxy-MeBmt]1-[Val]2-ciclosporin DK0874621T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9601120.0A GB9601120D0 (en)	1996-01-19	1996-01-19	Organic compounds
PCT/EP1997/000252 WO1997025977A1 (en)	1996-01-19	1997-01-20	Pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
DK0874621T3 true DK0874621T3 (da)	2003-09-01

Family

ID=10787276

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK02022257T DK1273289T3 (da)	1996-01-19	1997-01-20	Farmaceutiske sammensætninger indeholdende ascomycinderivater
DK97901563T DK0874621T3 (da)	1996-01-19	1997-01-20	Lægemiddelemulsion indeholdende [3'-desoxy-3-oxy-MeBmt]1-[Val]2-ciclosporin
DK05018663.4T DK1679064T3 (da)	1996-01-19	1997-01-20	Farmaceutiske sammensætninger indeholdende rapamycinderivater
DK02022256T DK1273288T3 (da)	1996-01-19	1997-01-20	Lægemiddelsammensætning indeholdende rapamycinderivater

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK02022257T DK1273289T3 (da)	1996-01-19	1997-01-20	Farmaceutiske sammensætninger indeholdende ascomycinderivater

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK05018663.4T DK1679064T3 (da)	1996-01-19	1997-01-20	Farmaceutiske sammensætninger indeholdende rapamycinderivater
DK02022256T DK1273288T3 (da)	1996-01-19	1997-01-20	Lægemiddelsammensætning indeholdende rapamycinderivater

Country Status (14)

Country	Link
US (2)	US6239102B1 (da)
EP (4)	EP0874621B1 (da)
JP (2)	JP4077386B2 (da)
KR (1)	KR100485146B1 (da)
AT (4)	ATE310504T1 (da)
AU (1)	AU1543497A (da)
CA (2)	CA2240339C (da)
DE (3)	DE69734253T2 (da)
DK (4)	DK1273289T3 (da)
ES (4)	ES2365734T3 (da)
GB (1)	GB9601120D0 (da)
HK (2)	HK1054183B (da)
PT (2)	PT874621E (da)
WO (1)	WO1997025977A1 (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5660858A (en) *	1996-04-03	1997-08-26	Research Triangle Pharmaceuticals	Cyclosporin emulsions
PT956034E (pt)	1996-07-30	2002-12-31	Novartis Ag	Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
US20030199425A1 (en) *	1997-06-27	2003-10-23	Desai Neil P.	Compositions and methods for treatment of hyperplasia
US20030220234A1 (en)	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
WO1999029316A1 (en)	1997-12-10	1999-06-17	Severson, Mary, L.	Pharmaceutical compositions containing an omega-3 fatty acid oil
DE19810655A1 (de) *	1998-03-12	1999-09-16	Univ Eberhard Karls	Arzneimittel mit einem Gehalt an Ciclosporin
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
AR018376A1 (es)	1998-05-26	2001-11-14	Novartis Ag	Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
US7265150B1 (en) *	1998-08-14	2007-09-04	Gpi Nil Holdings Inc.	Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6376517B1 (en) *	1998-08-14	2002-04-23	Gpi Nil Holdings, Inc.	Pipecolic acid derivatives for vision and memory disorders
US7063857B1 (en)	1999-04-30	2006-06-20	Sucampo Ag	Use of macrolide compounds for the treatment of dry eye
WO2000066122A1 (en) *	1999-04-30	2000-11-09	Sucampo Ag	Use of macrolide compounds for the treatment of dry eye
DE60044717D1 (de)	1999-05-10	2010-09-02	Paolo Brenner	Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
US6720001B2 (en) *	1999-10-18	2004-04-13	Lipocine, Inc.	Emulsion compositions for polyfunctional active ingredients
NZ525243A (en)	2000-10-31	2005-01-28	Pharma Mar S	A lyophilised formulation comprising kahalalide F, a peptide isolated from a herbivorous marine species of mollusc, Elysia rufescens, to treat cancer
MX368013B (es)	2001-02-19	2019-09-13	Novartis Ag	Tratamiento de cáncer.
US20050019372A1 (en) *	2001-07-10	2005-01-27	Barbara E Corkey	Modified-fat nutritional products useful preventing or treating obesity
US20040137066A1 (en) *	2001-11-26	2004-07-15	Swaminathan Jayaraman	Rationally designed therapeutic intravascular implant coating
US6641611B2 (en)	2001-11-26	2003-11-04	Swaminathan Jayaraman	Therapeutic coating for an intravascular implant
MXPA04003625A (es)	2001-10-19	2004-12-02	Sotechnika Inc	Sintesis de analogos de ciclosporina.
JP2006522007A (ja) *	2002-11-15	2006-09-28	ノバルティスアクチエンゲゼルシャフト	ドラッグ・デリバリー・システム
GB0307866D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Pharmaceutical composition
GB0307867D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Pharmaceutical composition
KR20060085246A (ko) *	2003-09-18	2006-07-26	마커사이트, 인코포레이티드	경공막 전달
WO2006135415A2 (en) *	2004-09-08	2006-12-21	University Of Florida Research Foundation, Inc.	Micelles and nanoemulsions for preventative and reactive treatment of atherosclerosis
GB0428151D0 (en)	2004-12-22	2005-01-26	Novartis Ag	Organic compounds
US8663639B2 (en) *	2005-02-09	2014-03-04	Santen Pharmaceutical Co., Ltd.	Formulations for treating ocular diseases and conditions
DK1848431T3 (da) *	2005-02-09	2016-04-18	Santen Pharmaceutical Co Ltd	Flydende formuleringer til behandling af sygdomme eller tilstande
GB0504995D0 (en) *	2005-03-11	2005-04-20	Biotica Tech Ltd	Use of a compound
KR20140093764A (ko)	2006-02-09	2014-07-28	산텐 세이야꾸 가부시키가이샤	안정한 제제와 그 제조 및 사용 방법
ES2563288T3 (es)	2006-03-23	2016-03-14	Santen Pharmaceutical Co., Ltd	Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
US7883855B2 (en) *	2006-07-21	2011-02-08	Abbott Laboratories	Immunosuppressant drug extraction reagent for immunoassays
US8414909B2 (en) *	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
EP2322235A1 (en) *	2006-11-20	2011-05-18	Lutonix, Inc.	Drug releasing coatings for medical devices
EP2118656B1 (en) *	2006-12-29	2012-08-29	Abbott Laboratories	Improved assay for immunosuppressant drugs
ES2405364T3 (es)	2006-12-29	2013-05-30	Abbott Laboratories	Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera
WO2008082984A2 (en)	2006-12-29	2008-07-10	Abbott Laboratories	Non-denaturing lysis reagent for use with capture-in-solution immunoassay
US7914999B2 (en) *	2006-12-29	2011-03-29	Abbott Laboratories	Non-denaturing lysis reagent
FR2911069B1 (fr) *	2007-01-09	2009-04-03	Physica Pharma Soc Par Actions	Composition pharmaceutique parenterale et son procede de preparation
US20080265343A1 (en) *	2007-04-26	2008-10-30	International Business Machines Corporation	Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
JP5753784B2 (ja) *	2008-10-10	2015-07-22	ダラ・バイオサイエンシズ，インコーポレイテッド	スピカマイシン誘導体を用いて疼痛を治療又は予防する方法
EP2682106A1 (en)	2012-07-03	2014-01-08	Phares Pharmaceutical Research N.V.	Method of solubilizing biologically active compounds
AU2014209141B2 (en)	2013-01-24	2018-05-10	Palvella Therapeutics, Inc.	Compositions for transdermal delivery of mTOR inhibitors
HUP1400075A2 (hu)	2014-02-14	2015-08-28	Druggability Technologies Ip Holdco Jersey Ltd	Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
AU2017350499B2 (en)	2016-10-28	2023-08-10	Les Laboratoires Servier	Liposomal formulation for use in the treatment of cancer
EP3565520B1 (en)	2017-01-06	2026-02-25	Palvella Therapeutics, Inc.	Anhydrous compositions of mtor inhibitors and methods of use
US11000513B2 (en)	2018-07-02	2021-05-11	Palvella Therapeutics, Inc.	Anhydrous compositions of mTOR inhibitors and methods of use
KR102003183B1 (ko)	2019-02-27	2019-07-24	배영진	안면마스크

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE296122C (da) *
US4707470A (en)	1985-05-17	1987-11-17	Smithkline Beckman Corporation	Polyene antibiotic emulsion formulation
CA1323306C (en)	1987-03-05	1993-10-19	Mircea C. Popescu	Pharmacological agent-lipid solution preparation
DE3884470T2 (de) *	1987-06-17	1994-03-10	Sandoz Ag	Cyclosporine und deren Benutzung als Arzneimittel.
WO1989002265A1 (fr)	1987-09-07	1989-03-23	Teijin Limited	Emulsion grasse contenant un medicament, du type prepare immediatement avant l'utilisation, et procede de preparation d'une telle emulsion grasse contenant un medicament
IL88076A (en)	1987-10-28	1993-01-14	Nippon Shinyaku Co Ltd	Fat emulsions as drug carriers
AU598958B2 (en)	1987-11-12	1990-07-05	Vestar, Inc.	Improved amphotericin b liposome preparation
EP0356399A3 (en) *	1988-08-26	1991-03-20	Sandoz Ag	Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
KR0148748B1 (ko)	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
DD295766A5 (de) *	1988-10-10	1991-11-14	Arzneimittelwerk Dresden Gmbh,De	Verfahren zur herstellung galenischer arzneiformen von ciclosporinen
JP2502719B2 (ja)	1988-12-28	1996-05-29	集合住宅用新材料・機器システム開発技術研究組合	冷暖給湯ヒ―トポンプシステム
DK0406791T3 (da) *	1989-07-05	1995-03-27	Fujisawa Pharmaceutical Co	Vandigt flydende præparat til ekstern anvendelse
JPH03147892A (ja)	1989-11-06	1991-06-24	Mitsubishi Rayon Co Ltd	昇華性分散染料易染性樹脂組成物
DK0427680T3 (da) *	1989-11-09	1995-12-18	Sandoz Ltd	Heteroatom-holdige cykliske forbindelser
US5352671A (en) *	1989-11-09	1994-10-04	Sandoz Ltd.	Heteroatoms-containing tricyclic compounds
JPH04253907A (ja) *	1990-05-23	1992-09-09	Green Cross Corp:The	静脈注射用免疫抑制剤
CA2054983A1 (en)	1990-11-08	1992-05-09	Sotoo Asakura	Suspendible composition and process for preparing the same
MX9201782A (es)	1991-04-19	1992-10-01	Sandoz Ag	Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
ZA924953B (en)	1991-07-25	1993-04-28	Univ Louisville Res Found	Method of treating ocular inflammation
US5457111A (en) *	1991-09-05	1995-10-10	Abbott Laboratories	Macrocyclic immunomodulators
EP0658344B1 (en)	1991-10-31	2000-01-05	Fujisawa Pharmaceutical Co., Ltd.	Liposome preparation containing tricyclic compound
GB9208712D0 (en) *	1992-04-22	1992-06-10	Sandoz Ltd	Pharmaceutical compositions containing cyclosporin derivates
US5527537A (en)	1992-05-18	1996-06-18	Dietl; Hans	Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and a process for its production
PT589843E (pt) *	1992-09-25	2002-04-29	Novartis Ag	Composicoes farmaceuticas contendo ciclosporinas
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
JPH06183970A (ja) *	1992-12-16	1994-07-05	Fujisawa Pharmaceut Co Ltd	医薬用組成物
CH686761A5 (de) *	1993-05-27	1996-06-28	Sandoz Ag	Galenische Formulierungen.
GB2278780B (en) *	1993-05-27	1998-10-14	Sandoz Ltd	Macrolide formulations
AU688782B2 (en) *	1993-09-30	1998-03-19	Wyeth	Rapamycin formulations for oral administration
FI100692B (fi) *	1994-05-24	1998-02-13	Leiras Oy	Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
CN100335063C (zh) *	1994-10-26	2007-09-05	诺瓦蒂斯有限公司	药物组合物

1996
- 1996-01-19 GB GBGB9601120.0A patent/GB9601120D0/en active Pending
1997
- 1997-01-20 CA CA2240339A patent/CA2240339C/en not_active Expired - Lifetime
- 1997-01-20 DK DK02022257T patent/DK1273289T3/da active
- 1997-01-20 WO PCT/EP1997/000252 patent/WO1997025977A1/en not_active Ceased
- 1997-01-20 EP EP97901563A patent/EP0874621B1/en not_active Expired - Lifetime
- 1997-01-20 ES ES05018663T patent/ES2365734T3/es not_active Expired - Lifetime
- 1997-01-20 DK DK97901563T patent/DK0874621T3/da active
- 1997-01-20 EP EP02022256A patent/EP1273288B1/en not_active Expired - Lifetime
- 1997-01-20 US US09/091,072 patent/US6239102B1/en not_active Ceased
- 1997-01-20 ES ES97901563T patent/ES2199338T3/es not_active Expired - Lifetime
- 1997-01-20 AT AT02022257T patent/ATE310504T1/de active
- 1997-01-20 PT PT97901563T patent/PT874621E/pt unknown
- 1997-01-20 AT AT97901563T patent/ATE239449T1/de active
- 1997-01-20 AT AT05018663T patent/ATE510532T1/de active
- 1997-01-20 KR KR10-1998-0704696A patent/KR100485146B1/ko not_active Expired - Lifetime
- 1997-01-20 DE DE69734253T patent/DE69734253T2/de not_active Expired - Lifetime
- 1997-01-20 AT AT02022256T patent/ATE304842T1/de active
- 1997-01-20 DE DE69734742T patent/DE69734742T2/de not_active Expired - Lifetime
- 1997-01-20 CA CA002678707A patent/CA2678707A1/en not_active Abandoned
- 1997-01-20 DK DK05018663.4T patent/DK1679064T3/da active
- 1997-01-20 EP EP05018663A patent/EP1679064B1/en not_active Expired - Lifetime
- 1997-01-20 AU AU15434/97A patent/AU1543497A/en not_active Abandoned
- 1997-01-20 EP EP02022257A patent/EP1273289B1/en not_active Expired - Lifetime
- 1997-01-20 DE DE69721729T patent/DE69721729T2/de not_active Expired - Lifetime
- 1997-01-20 PT PT05018663T patent/PT1679064E/pt unknown
- 1997-01-20 DK DK02022256T patent/DK1273288T3/da active
- 1997-01-20 ES ES02022257T patent/ES2253483T3/es not_active Expired - Lifetime
- 1997-01-20 ES ES02022256T patent/ES2247245T3/es not_active Expired - Lifetime
- 1997-01-20 US US10/345,665 patent/USRE42014E1/en not_active Expired - Lifetime
1999
- 1999-02-05 HK HK03104827.8A patent/HK1054183B/en not_active IP Right Cessation
- 1999-02-05 HK HK03104828.7A patent/HK1053973B/en not_active IP Right Cessation
2003
- 2003-09-29 JP JP2003337458A patent/JP4077386B2/ja not_active Expired - Lifetime
2007
- 2007-06-19 JP JP2007161630A patent/JP2007246543A/ja active Pending

Also Published As

Publication number	Publication date
PT874621E (pt)	2003-09-30
EP1273289A1 (en)	2003-01-08
HK1054183B (en)	2006-07-28
EP1679064B1 (en)	2011-05-25
EP0874621B1 (en)	2003-05-07
WO1997025977A1 (en)	1997-07-24
HK1015277A1 (en)	1999-10-15
ATE310504T1 (de)	2005-12-15
JP3763581B2 (ja)	2006-04-05
ATE304842T1 (de)	2005-10-15
EP1679064A3 (en)	2009-10-07
CA2240339A1 (en)	1997-07-24
CA2240339C (en)	2010-11-16
ATE510532T1 (de)	2011-06-15
HK1053973B (en)	2006-09-29
JP2007246543A (ja)	2007-09-27
ATE239449T1 (de)	2003-05-15
AU1543497A (en)	1997-08-11
HK1054183A1 (en)	2003-11-21
EP1273288A1 (en)	2003-01-08
USRE42014E1 (en)	2010-12-28
DE69734742D1 (de)	2005-12-29
DK1679064T3 (da)	2011-09-12
KR19990076603A (ko)	1999-10-15
DE69734253D1 (de)	2006-02-02
DE69734742T2 (de)	2006-07-27
EP1679064A2 (en)	2006-07-12
EP1273289B1 (en)	2005-11-23
DE69721729D1 (de)	2003-06-12
HK1053973A1 (en)	2003-11-14
DE69721729T2 (de)	2003-12-11
KR100485146B1 (ko)	2005-10-12
DK1273289T3 (da)	2006-03-20
GB9601120D0 (en)	1996-03-20
ES2247245T3 (es)	2006-03-01
US6239102B1 (en)	2001-05-29
ES2365734T3 (es)	2011-10-10
JP4077386B2 (ja)	2008-04-16
ES2199338T3 (es)	2004-02-16
DK1273288T3 (da)	2005-11-21
PT1679064E (pt)	2011-07-25
EP1273288B1 (en)	2005-09-21
JP2000503655A (ja)	2000-03-28
CA2678707A1 (en)	1997-07-24
EP0874621A1 (en)	1998-11-04
ES2253483T3 (es)	2006-06-01
DE69734253T2 (de)	2006-07-06
JP2004107350A (ja)	2004-04-08

Publication	Publication Date	Title
DK0874621T3 (da)	2003-09-01	Lægemiddelemulsion indeholdende [3'-desoxy-3-oxy-MeBmt]1-[Val]2-ciclosporin
US5059593A (en)	1991-10-22	Pour-on formulations which are active against ticks
US5612056A (en)	1997-03-18	Transdermal formulations
US4096262A (en)	1978-06-20	Pour-on anthelmintics
US5164406A (en)	1992-11-17	Method for enhancing transdermal penetration and compositions useful therein
KR950007859A (ko)	1995-04-15	경구 투여용 라파마이신 제형
JP2001521886A (ja)	2001-11-13	プロスタグランジンｅ１送達のための局所組成物
BG104560A (en)	2001-04-30	Long active injectable formulations containing hydrogenated castor oil
KR970706021A (ko)	1997-11-03	N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형제제(MEDICINAL ADJUVANTS CONSISTIONG OF AN N-SUBSTITUED-o-TOLUIDING DERIVANTIVE, AND PERCUTANEOUSLY ABSORBALE PREPARATIONS COMPRISING THE ADJUVANTS)
DK0525307T3 (da)	1996-04-01	Stabile præparater til parenteral indgivelse og deres anvendelse
JPH05246893A (ja)	1993-09-24	水素化ひまし油を含む長期持続性注射製剤
US4594357A (en)	1986-06-10	Depot antiinflammatory agents
JPH0113681B2 (da)	1989-03-07
US20060121118A1 (en)	2006-06-08	Antimycotic gel having high active compound release
US4127663A (en)	1978-11-28	Thiazole derivatives to treat inflammation
US5034420A (en)	1991-07-23	Compositions and method for stabilization of anthralin comprising the addition of an oil soluble antioxidant and an anionic surfactant
IE841440L (en)	1984-12-09	Stabilisation of anthralin compositions
NO971879L (no)	1997-06-23	Preparat for transdermal administrasjon
KR880013874A (ko)	1988-12-22	카르복실산 에스테르, 그의 제조방법 및 그것을 유효 성분으로 함유하는 살충제
KR100600402B1 (ko)	2006-07-14	피부 도포용 이버멕틴 조성물 및 그 제조방법
KR100569858B1 (ko)	2006-04-11	경피투여용 항구토제 조성물
JPH08151308A (ja)	1996-06-11	有害生物防除剤
KR830006178A (ko)	1983-09-20	부작용감소와 약효시간이 연장된 새로운 기관지 진정제의 제조방법
SI8712284B (sl)	1999-06-30	Pripravki za nazalno uporabo in postopki za njihovo pridobivanje